Anthropic Taps Novartis CEO for Board in Healthcare Expansion Push Ahead of Potential IPO

Anthropic has appointed Vas Narasimhan, the chief executive of Swiss pharmaceutical giant Novartis, to its board of directors, marking the AI company's second major board addition in recent months. The move signals Anthropic's serious pivot toward healthcare and positions the company ahead of a potential initial public offering that could happen as soon as 2026. Narasimhan brings heavyweight pharma credentials to the table—he's overseen the development and approval of more than 35 novel medicines in one of the world's most heavily regulated industries, giving Anthropic credibility as it expands its enterprise healthcare strategy.

This isn't Anthropic's first foray into pharma partnerships. The company has already struck deals with heavy hitters like Eli Lilly, Novo Nordisk, and Genmab, all aimed at dramatically shortening drug development life cycles. In January, Anthropic rolled out new Claude features specifically designed for healthcare providers, insurers, and health tech companies, while also beefing up Claude's capabilities in life sciences to handle clinical trial management and regulatory operations. The company's commitment runs even deeper—just this month, Anthropic quietly acquired Coefficient Bio, a biotech startup, further cementing its position in the life sciences space.

The board reinforcements come as Anthropic prepares for a major capital event. Chris Liddell, a former Microsoft and General Motors executive, joined the board back in February, suggesting the company is deliberately building out seasoned operational and business leadership ahead of going public. Narasimhan's addition speaks to a deliberate strategy: Anthropic isn't just chasing AI applications in healthcare as an afterthought—it's betting that AI can crack some of science's hardest problems, from disease biology to drug design.